The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
Sclerosing epithelioid fibrosarcoma is an ultra-rare and aggressive high-grade fibrosarcoma that was originally described in 1995. More than 100 cases are documented worldwide, with the most extensive case series reporting a high rate of recurrence and metastasis. ALK mutations are commonly seen in soft-tissue sarcomas; however, this is the first known case of an ALK V757M mutation. Here, we present a case using crizotinib in treating an ALK-positive sclerosing epithelioid fibrosarcoma refractory to all traditional treatment options.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report ; volume:16 ; number:1 ; year:2023 ; pages:746-752 ; extent:7
Case reports in oncology ; 16, Heft 1 (2023), 746-752 (gesamt 7)
- Creator
-
Badran, Ahmed
Steele, Clara
Alquaydheb, Hisham
Ba Theeb, Ahmed
Bawazir, Abdulmalek
Elshenawy, Mahmoud A.
Atallah, Jean Paul
- DOI
-
10.1159/000532099
- URN
-
urn:nbn:de:101:1-2023122723533616643052
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Badran, Ahmed
- Steele, Clara
- Alquaydheb, Hisham
- Ba Theeb, Ahmed
- Bawazir, Abdulmalek
- Elshenawy, Mahmoud A.
- Atallah, Jean Paul